BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12180815)

  • 1. Rejection of grafts with no H-2 disparity in TAP1 mutant mice: CD4 T cells are important effector cells and self H-2b class I molecules are target.
    Suárez IM; Benvenutti LA; Noronh I; Van Kaer L; Kalil J; Coelho V
    Transpl Immunol; 2002 May; 9(2-4):101-10. PubMed ID: 12180815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoreactivity to self H-2Kb peptides in TAP1 mice. Intravenous administration of H-2Kb class I-derived peptides induces long-term survival of grafts from C57BL/6 donors.
    Marrero I; Benvenutti LA; Kalil J; Coelho V
    Immunology; 2005 Aug; 115(4):484-94. PubMed ID: 16011517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rejection of grafts without histocompatibility antigen disparity by TAP1-/- mice: a role for CD4+ T cells.
    Marrero I; Benvenutti LA; Noronha I; Kalil J; Coelho V
    Transplant Proc; 2004 May; 36(4):999-1000. PubMed ID: 15194347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAP1-/- mice present oligoclonal BV-BJ expansions following the rejection of grafts bearing self antigens.
    Marrero I; Huffman D; Kalil J; Sercarz EE; Coelho V
    Immunology; 2006 Aug; 118(4):461-71. PubMed ID: 16895555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts.
    Wise M; Zelenika D; Bemelman F; Latinne D; Bazin H; Cobbold S; Waldmann H
    Eur J Immunol; 1999 Jan; 29(1):156-67. PubMed ID: 9933097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice.
    Ljunggren HG; Van Kaer L; Sabatine MS; Auchincloss H; Tonegawa S; Ploegh HL
    Int Immunol; 1995 Jun; 7(6):975-84. PubMed ID: 7577806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ effector cells responding to residual class I antigens, with help from CD4+ cells stimulated indirectly, cause rejection of "major histocompatibility complex-deficient" skin grafts.
    Lee RS; Grusby MJ; Laufer TM; Colvin R; Glimcher LH; Auchincloss H
    Transplantation; 1997 Apr; 63(8):1123-33. PubMed ID: 9133474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific tolerance induction of allo-K(b)-skin grafts by FK506 in the CD8-depleted H-2(k) recipients required low amounts of K(b)-antigen.
    Chen BG; Liu Z; Wu Y
    Transpl Immunol; 2005 Oct; 15(1):9-16. PubMed ID: 16223668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptively transferred CD4+ lymphocytes from CD8 -/- mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts.
    Dalloul AH; Chmouzis E; Ngo K; Fung-Leung WP
    J Immunol; 1996 Jun; 156(11):4114-9. PubMed ID: 8666777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self major histocompatibility complex class I antigens expressed solely in lymphoid cells do not induce tolerance in the CD4+ T cell compartment.
    Schulz R; Mellor AL
    J Exp Med; 1996 Oct; 184(4):1573-8. PubMed ID: 8879232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential reactivity of residual CD8+ T lymphocytes in TAP1 and beta 2-microglobulin mutant mice.
    Ljunggren HG; Van Kaer L; Ashton-Rickardt PG; Tonegawa S; Ploegh HL
    Eur J Immunol; 1995 Jan; 25(1):174-8. PubMed ID: 7843229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin graft rejection elicited by beta 2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates.
    Surquin M; Le Moine A; Flamand V; Nagy N; Rombaut K; Demoor FX; Stordeur P; Salmon I; Guéry JC; Goldman M; Abramowicz D
    J Immunol; 2002 Jul; 169(1):500-6. PubMed ID: 12077281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rejection of skin allografts by CD4+ T cells is antigen-specific and requires expression of target alloantigen on Ia- epidermal cells.
    Rosenberg AS; Katz SI; Singer A
    J Immunol; 1989 Oct; 143(8):2452-6. PubMed ID: 2477443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymocyte antigens do not induce tolerance in the CD4+ T cell compartment.
    Jhaver KG; Chandler P; Simpson E; Mellor AL
    J Immunol; 1999 Nov; 163(9):4851-8. PubMed ID: 10528186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential involvement of CD4+ cells in mediating skin graft rejection against different amounts of transgenic H-2K(b) antigen.
    Kawai M; Obata Y; Hamasima N; Takahashi T; Uenaka A; Monden M; Mori T; Shiku H; Nakayama E
    J Exp Med; 1991 Jan; 173(1):261-4. PubMed ID: 1670639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptides derived from alpha-helices of allogeneic class I major histocompatibility complex antigens are potent inducers of CD4+ and CD8+ T cell and B cell responses after cardiac allograft rejection.
    Shirwan H; Leamer M; Wang HK; Makowka L; Cramer DV
    Transplantation; 1995 Feb; 59(3):401-10. PubMed ID: 7871571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The critical role of mouse CD4+ cells in the rejection of highly disparate xenogeneic pig thymus grafts.
    Zhao Y; Swenson K; Wekerle T; Rodriguez-Barbosa JI; Arn JS; Sykes M
    Xenotransplantation; 2000 May; 7(2):129-37. PubMed ID: 10961297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular basis of skin allograft rejection across a class I major histocompatibility barrier in mice depleted of CD8+ T cells in vivo.
    Rosenberg AS; Munitz TI; Maniero TG; Singer A
    J Exp Med; 1991 Jun; 173(6):1463-71. PubMed ID: 1674524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAP1-deficient mice select a CD8+ T cell repertoire that displays both diversity and peptide specificity.
    Sandberg JK; Chambers BJ; Van Kaer L; Kärre K; Ljunggren HG
    Eur J Immunol; 1996 Feb; 26(2):288-93. PubMed ID: 8617293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cells contribute to the skin graft rejection promoted by CD4+ T cells activated through the indirect allorecognition pathway.
    Ito A; Shimura H; Nitahara A; Tomiyama K; Ito M; Kanekura T; Okumura K; Yagita H; Kawai K
    Int Immunol; 2008 Oct; 20(10):1343-9. PubMed ID: 18697765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.